Captrust Financial Advisors Grifols Sa Transaction History

Captrust Financial Advisors

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$7.71 - $11.56 $101,116 - $151,609	13,115 New	13,115 $151,000
Q2 2022 Aug 23, 2022	SELL	$10.6 - $13.28 $10,939 - $13,704	-1,032 Reduced 49.47%	1,054 $13,000
Q2 2022 Aug 16, 2022	BUY	$10.6 - $13.28 $13,387 - $16,772	1,263 Added 153.46%	2,086 $25,000
Q1 2022 May 16, 2022	SELL	$10.37 - $12.73 $22,534 - $27,662	-2,173 Reduced 72.53%	823 $10,000
Q4 2021 Feb 14, 2022	BUY	$10.21 - $15.27 $29,976 - $44,832	2,936 Added 4893.33%	2,996 $34,000
Q3 2021 Nov 16, 2021	SELL	$14.07 - $17.3 $281 - $346	-20 Reduced 25.0%	60 $1,000
Q1 2021 May 17, 2021	BUY	$15.15 - $19.78 $1,212 - $1,582	80 New	80 $1,000

164

140M

288K

389K

Ticker GRFS
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 678,910,976
Market Cap $5.33B
Description
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solut...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.